Sarcoma, Soft Tissue Sarcoma (STS), Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS), Dedifferentiated Liposarcoma (DDLPS)
Conditions
Keywords
TIL, Tumor Infiltrating Lymphocytes, Cell Therapy, Cellular Immuno-therapy, IL2, Lifileucel, Sarcoma, Soft Tissue Sarcoma, Advanced Soft Tissue Sarcoma, LN-145, Non-myeloablative lymphodepletion (NMALD), SARATOGA, Undifferentiated pleomorphic sarcoma (UPS), Dedifferentiated liposarcoma (DDLPS)
Brief summary
A study of lifileucel (tumor-infiltrating lymphocytes) in adults with advanced soft tissue sarcoma ('SARATOGA')
Detailed description
The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated soft tissue sarcoma. The length of the study for each participant may be up to 5 calendar years after receiving lifileucel. After Screening, each participant will have surgery to remove some tumor pieces that will be used to make the lifileucel, followed by a baseline visit prior to study treatment. Participants will then receive the lifileucel treatment regimen. This includes 2 drugs (cyclophosphamide and fludarabine) for up to 5 days to decrease lymphocytes in the body, the lifileucel infusion (1 day), and up to 4 days of aldesleukin to boost the activity of the lifileucel. Study visits will be every 6 weeks for 6 months, then every 3 months until 5 calendar years after the lifileucel infusion.
Interventions
BIOLOGICALLifileucel
Study intervention will begin with a tumor resection from which lifileucel will be generated. The lifileucel regimen consists of a preparative NMA-LD regimen (ie, cyclophosphamide with mesna followed by fludarabine), the lifileucel infusion, and an abbreviated course of aldesleukin (interleukin-2).
Sponsors
Iovance Biotherapeutics, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
16 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Participant must be ≥ 16 years of age at the time of signing the informed consent and assent. * Participants who are \> 70 years of age may be allowed to enroll after the investigator discusses with the medical monitor. * Participant must have a confirmed diagnosis of histologically confirmed unresectable or metastatic UPS (Cohort 1) or DDLPS (Cohort 2), with or without a well-differentiated component, who have received ≥ 1 and a maximum of 3 prior systemic therapies, including ≥ 1 anthracycline-based regimen. * Participant has demonstrated progressive disease on or after the last line of therapy. * Participant is assessed as having at least one resectable lesion (or aggregate lesions) with an estimated minimum diameter of 1.5 cm (short axis) for lifileucel generation. * Following tumor resection for lifileucel generation, the participant will have at least one measurable lesion, as defined by RECIST v1.1 at Baseline. * Participant is expected to achieve washout from investigational or anticancer therapy(ies). * If the participant has preplanned surgical procedure(s), the procedure will take place at least 14 days (for major operative procedures) prior to the tumor resection. Wound healing will have occurred, and all complications will have resolved at the time of tumor resection. * Participant has recovered from all prior anticancer treatment-related AEs to Grade ≤ 1(per NCI-CTCAE), except for peripheral neuropathy, alopecia, or vitiligo. * Participants of childbearing potential or those with partners of childbearing potential must be willing to practice an approved method of highly effective birth control. * Participants must have adequate organ function. * Participant is willing to receive optimal supportive care, including intensive care, from enrollment until the first post-treatment tumor assessment.
Exclusion criteria
* Participant has symptomatic untreated brain metastases. * The participant has an ECOG performance status of ≥ 2, a need for urgent therapy due to rapidly progressive disease or tumor mass effect, or an estimated life expectancy of\< 6 months. * Participant has an active medical illness(es) that, in the opinion of the investigator, would pose increased risks for study participation. * Participant has any form of primary immunodeficiency (eg, severe combined immunodeficiency disease \[SCID\] or AIDS). * Participant has a history of hypersensitivity to any component of the study intervention. * Participant had another primary malignancy within the previous 3 years (except for those that do not require treatment or have been curatively treated \> 1 year ago, and in the judgment of the investigator does not pose a significant risk of recurrence. Other protocol defined inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective Response Rate | 5 years | To evaluate the efficacy of lifileucel as measured by ORR per RECIST v1.1 as assessed by the IRC |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Complete Response Rate | 5 years | To evaluate the efficacy of lifileucel as measured by CR rate per RECIST v1.1 as assessed by the IRC |
| Duration of Response | 5 years | To evaluate the efficacy of lifileucel as measured by DOR per RECIST v1.1 as assessed by the IRC |
| Disease Control Rate | 5 years | To evaluate the efficacy of lifileucel as measured by DCR per RECIST v1.1 as assessed by the IRC |
| Progression-Free Survival | 5 years | To evaluate the efficacy of lifileucel as measured by PFS per RECIST v1.1 as assessed by the IRC |
| Objective Response Rate | 5 years | To evaluate the efficacy of lifileucel as measured by ORR per RECIST v1.1 as assessed by the investigators |
| Overall Survival | 5 years | To evaluate the efficacy of lifileucel as measured by OS |
| Adverse Events | 5 years | To evaluate safety and tolerability of lifileucel |
Contacts
CONTACTIovance Biotherapeutics Study Team
Outcome results
None listed